InvestorsHub Logo
Followers 27
Posts 2742
Boards Moderated 0
Alias Born 03/17/2017

Re: finesand post# 23837

Tuesday, 07/31/2018 9:45:27 PM

Tuesday, July 31, 2018 9:45:27 PM

Post# of 233151
Compilation Update + Catalyst Calendar

Update Log,

2018-06-23 - Evaluation (needs update soon),

2018-07-29 - 2018 10-K Brief Overview,

2018-07-19 - Presentation at Singular Summer Solstice 2018 Conference,

2018-07-17 - Investment Community Conference Call,

2018-07-22 - Comparison HIV-1 Anti-infective antibodies,

2018-06-30 - Pro 140 Related Publications,

2018-06-26 - Pro 140 Metastatic Cancer Suppression,

2018-06-18 - The return of PRO 140, a CCR5-directed mAb,

2018-06-14 - Pro 140 Covering Scientists,

2018-06-23 - Insider Ownership,

2018-06-22 - PRO 140 SC Combo about to arrive,

2018-02-20 - Pro 140 Phase 2b/3 Pivotal PE Achieved,

2018-04-10 - CEO Letter to Investor


Calendar from July 2018 Presentation, PRs & Notes

- DONE: CD02 Pivotal Phase 3 Endpoint Achieved (ASM Microbe late breaker) (Source: CYDY)
- DONE: FDA meeting until end of June '18 to discus BLA/NDA presenting trial data, determining submission plan (Source: CYDY)
- DONE: Full CD02 Trial Data Disclosure via 7/16 PR.
- DONE: Investor Conference Call 7/17 (Source: CYDY IR)
- DONE: 150pt 24weeks safety data, 89 CD03 pts from 2017-10-17 completed on 2018-04-03 (7/17 CC + Deduction)
- DONE: CD03 Enrollment Completed 303pt, but continuing enrollment. 48 weeks complete 2019-06-18 2Q19-3Q19 (7/17 CC + Deduction)
- 8/30: GvHD 30 day data review of 10 additional pts by iDMC soon (CYDY 7/19 CC)???
- 2H18: Publication Studies – CD02 Combo Primary Endpoint Study (Source: CYDY 7/19 CC)
- 2018: File for HIV Breakthrough Therapy Designation (BTD) (Source: CYDY 7/19 CC)
- 2018: IND Submission for Phase 2 in Colon Cancer & MS (Source: CYDY 7/19 CC)
- 1H19: BLA Submission for CD02 Combo (Source: CYDY 7/19 CC)

Expected Milestones:
- ~$70M financing of next 12 Month for HIV-1 and GvHD ex Cancer: Offering, Partnership, ..
- Final terms of ProstaGene acquisition (All share stake for Pestell, how much?)
- 150 pts safety data for Combo BLA (CYDY 7/17 CC)
- Pestell's Mice Data Pro 140 for Breast Cancer?
- CD03 Mono prelim data 2Q19?
- Combo BLA acceptance 2019
- Mono BLA filing 2019, acceptance 2020?


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News